Opicapone is a new-generation peripheral catechol-O-methyltransferase (COMT) inhibitor. Developed by the Portuguese pharmaceutical group Bial-Portela, it was first approved by the European Union (EU) in June 2016.As an adjunctive therapy to levodopa/dopa decarboxylase inhibitors (...